Biological products

• 

  Subject Areas on Research

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. 
  • A comparison of moment-based and probability-based criteria for assessment of follow-on biologics. 
  • A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. 
  • A general strategy for construction of both 2,6-cis- and 2,6-trans-disubstituted tetrahydropyrans: substrate-controlled asymmetric total synthesis of (+)-scanlonenyne 
  • A review of lipidation in the development of advanced protein and peptide therapeutics. 
  • A survey of multidisciplinary healthcare providers utilizing the KNOWintegrativeoncology.org educational platform. 
  • A synthetic mechanogenetic gene circuit for autonomous drug delivery in engineered tissues. 
  • ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. 
  • Absence of macrophage involvement in the passive serum therapy of Friend leukemia virus-induced disease. 
  • Advances in Wound Management. 
  • Advances in the synthesis of glycosidic macrolides: clavosolides A-D and cyanolide A. 
  • Advances in the treatment of inflammatory arthritis. 
  • An overview of naturally occurring histone deacetylase inhibitors. 
  • Antirheumatic medications in pregnancy and breastfeeding. 
  • Application of the parallel line assay to assessment of biosimilar products based on binary endpoints. 
  • Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. 
  • Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Biologics in organ transplantation. 
  • Bovine versus porcine acellular dermal matrix for abdominal wall herniorrhaphy or bridging. 
  • C-C bond forming radical SAM enzymes involved in the construction of carbon skeletons of cofactors and natural products. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Catalytic enantioselective olefin metathesis in natural product synthesis. Chiral metal-based complexes that deliver high enantioselectivity and more. 
  • Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. 
  • Chemical logic of MraY inhibition by antibacterial nucleoside natural products. 
  • Cheminformatic Analysis of Natural Product Fragments. 
  • Chemography of natural product space. 
  • Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals. 
  • Clinical Improvements in Very Dry Skin from a Natural Ingredient-Based Moisturizing Cream Compared With a Leading Colloidal Oatmeal Control. 
  • Commentary: Biologic versus mechanical valves: Wandering in the dark. 
  • Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. 
  • Comparative effectiveness of surfactant preparations in premature infants. 
  • Comparative efficacy and safety of late surfactant preparations: a retrospective study. 
  • Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. 
  • Controlled release of biologics for the treatment of type 2 diabetes. 
  • Counting on natural products for drug design. 
  • Cryptic Phosphorylation-Mediated Divergent Biosynthesis of High-Carbon Sugar Nucleoside Antifungals. 
  • Cryptic phosphorylation in nucleoside natural product biosynthesis. 
  • Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. 
  • Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. 
  • Deorphaning the Macromolecular Targets of the Natural Anticancer Compound Doliculide. 
  • Design and stereoselective preparation of a new class of chiral olefin metathesis catalysts and application to enantioselective synthesis of quebrachamine: catalyst development inspired by natural product synthesis. 
  • Design considerations, architecture, and use of the Mini-Sentinel distributed data system. 
  • Discovery of Manassantin A Protein Targets Using Large-Scale Protein Folding and Stability Measurements. 
  • Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells. 
  • Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. 
  • Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancer. 
  • Evaluation of the Performance of a Nature-Based Sensitive Skin Regimen in Subjects With Clinically Diagnosed Sensitive Skin. 
  • Factors Associated With Initiation of Biologics in Patients With Axial Spondyloarthritis in an Urban Asian City: A PRESPOND Study. 
  • Factors Related to Biologic Adherence and Outcomes Among Moderate-to-Severe Asthma Patients. 
  • Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. 
  • Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). 
  • Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. 
  • Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. 
  • Injectable Therapies for Regional Melanoma. 
  • Introduction. Biologics in spine surgery. 
  • Investigating the Role of Class I Adenylate-Forming Enzymes in Natural Product Biosynthesis. 
  • Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. 
  • Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 
  • Largazole: from discovery to broad-spectrum therapy. 
  • Letter to the Editor Regarding Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. 
  • Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply. 
  • Linking Genes to Molecules in Eukaryotic Sources: An Endeavor to Expand Our Biosynthetic Repertoire. 
  • Microglassification™: a novel technique for protein dehydration. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Multiple hops move electrons from bacteria to rocks. 
  • Natural Skin Care Products as Adjunctive to Prescription Therapy in Moderate to Severe Rosacea 
  • Natural product synthesis at the interface of chemistry and biology. 
  • Natural products and chronic hepatitis C virus. 
  • Nonoperative and Operative Soft-Tissue and Cartilage Regeneration and Orthopaedic Biologics of the Foot and Ankle: An Orthoregeneration Network Foundation Review. 
  • North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. 
  • Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. 
  • Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. 
  • Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. 
  • Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. 
  • Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases. 
  • Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type. 
  • Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016. 
  • Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs. 
  • Radical Breakthroughs in Natural Product and Cofactor Biosynthesis. 
  • Reply to Vanhove et al. 
  • Retreatment with talimogene laherparepvec for advanced melanoma. 
  • Revealing the Macromolecular Targets of Fragment-Like Natural Products. 
  • Revealing the macromolecular targets of complex natural products. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. 
  • Role of natural product diversity in chemical biology. 
  • Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. 
  • Special Issue of Journal of Biopharmaceutical Statistics dedicated to 2016 Trends and Innovations in Clinical Trial Statistics (TICTS) Conference. 
  • Static and Dynamic Microscopy of the Chemical Stability and Aggregation State of Silver Nanowires in Components of Murine Pulmonary Surfactant. 
  • Statistical and regulatory considerations in assessments of interchangeability of biological drug products. 
  • Statistical assessment of biosimilar products. 
  • Statistical methods for assessment of biosimilarity using biomarker data. 
  • Statistical test for evaluation of biosimilarity in variability of follow-on biologics. 
  • Surfactant Administration in Preterm Infants: Drug Development Opportunities. 
  • Suture, synthetic, or biologic in contaminated ventral hernia repair. 
  • Synthesis of α,α'-trans-oxepanes through an organocatalytic oxa-conjugate addition reaction. 
  • Synthetic efforts towards the stereoselective synthesis of NF00659B₁ . 
  • Systematic assignment of the configuration of flexible natural products by spectroscopic and computational methods: the bistramide C analysis. 
  • Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. 
  • Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance. 
  • Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. 
  • The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 
  • The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. 
  • The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. 
  • Therapy of rheumatoid arthritis: new developments and trends. 
  • There is a role for industry-sponsored education in cardiology. 
  • Three-dimensional reconstruction of tubular myelin. 
  • Tides of inflammation: impact of biologics. 
  • Toward Generalizable Trajectory Planning for Human Intracerebral Trials and Therapy. 
  • Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. 
  • Ulcerative colitis. 
  • Updating Urinary Microbiome Analyses to Enhance Biologic Interpretation. 
  • Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. 
  • Using registries to identify adverse events in rheumatic diseases. 
  • What's next in the pipeline. 
• 

  Keywords of People

  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics